By Professor Kerry-Anne Rye

Journal articles

Tso C; Rye K; Barter P, 2010, 'Generation of Endothelial-like Cells from Endothelium-adherent Blood Monocytes', Heart, Lung and Circulation, 19, pp. S14 - S14, http://dx.doi.org/10.1016/j.hlc.2010.06.695

Zhang L; Cavigiolio G; Wang J; Rye K-A; Oda M; Ren G, 2010, 'Structure of 9.6nm Discoidal High-Density Lipoprotein Revealed by Individual-Particle Electron Tomography', Biophysical Journal, 98, pp. 440a - 440a, http://dx.doi.org/10.1016/j.bpj.2009.12.2391

Charlton F; Xu B; Makris A; Rye K-A; Hennessy A, 2010, 'T9.4 High density lipoproteins protect against TNF-alpha induced inhibition of trophoblast/tubular endothelial cell integration', Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health, 1, pp. S19 - S19, http://dx.doi.org/10.1016/s2210-7789(10)60087-6

Zerrad-Saadi A; Therond P; Chantepie S; Couturier M; Rye KA; Chapman MJ; Kontush A, 2009, 'HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: Relevance to inflammation and atherogenesis', Arteriosclerosis, Thrombosis, and Vascular Biology, 29, pp. 2169 - 2175, http://dx.doi.org/10.1161/ATVBAHA.109.194555

Chan DC; Lambert G; Barrett PHR; Rye KA; Ooi EMM; Watts GF, 2009, 'Plasma proprotein convertase subtilisin/kexin type 9: A marker of LDL apolipoprotein B-100 catabolism?', Clinical Chemistry, 55, pp. 2049 - 2052, http://dx.doi.org/10.1373/clinchem.2009.128645

Chan DC; Watts GF; Ooi EMM; Rye KA; Ji J; Johnson AG; Barrett PHR, 2009, 'Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome', Diabetes Care, 32, pp. 2111 - 2113, http://dx.doi.org/10.2337/dc09-0519

Peshavariya H; Dusting GJ; Di Bartolo B; Rye KA; Barter PJ; Jiang F, 2009, 'Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts', Free Radical Research, 43, pp. 772 - 782, http://dx.doi.org/10.1080/10715760903045304

Fryirs M; Barter PJ; Rye KA, 2009, 'Cholesterol metabolism and pancreatic β-cell function', Current Opinion in Lipidology, 20, pp. 159 - 164, http://dx.doi.org/10.1097/MOL.0b013e32832ac180

McGrath KCY; Li XH; Puranik R; Liong EC; Tan JTM; Dy VM; Dibartolo BA; Barter PJ; Rye KA; Heather AK, 2009, 'Role of 3β-hydroxysteroid-Δ24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells', Arteriosclerosis, Thrombosis, and Vascular Biology, 29, pp. 877 - 882, http://dx.doi.org/10.1161/ATVBAHA.109.184663

Rye KA; Bursill CA; Lambert G; Tabet F; Barter PJ, 2009, 'The metabolism and anti-atherogenic properties of HDL', Journal of Lipid Research, 50, http://dx.doi.org/10.1194/jlr.R800034-JLR200

Patel S; Drew BG; Nakhla S; Duffy SJ; Murphy AJ; Barter PJ; Rye KA; Chin-Dusting J; Hoang A; Sviridov D; Celermajer DS; Kingwell BA, 2009, 'Reconstituted High-Density Lipoprotein Increases Plasma High-Density Lipoprotein Anti-Inflammatory Properties and Cholesterol Efflux Capacity in Patients With Type 2 Diabetes', Journal of the American College of Cardiology, 53, pp. 962 - 971, http://dx.doi.org/10.1016/j.jacc.2008.12.008

Lambert G; Charlton F; Rye KA; Piper DE, 2009, 'Molecular basis of PCSK9 function', Atherosclerosis, 203, pp. 1 - 7, http://dx.doi.org/10.1016/j.atherosclerosis.2008.06.010

Kiya Y; Miura SI; Imaizumi S; Uehara Y; Matsuo Y; Abe S; Jimi S; Urata H; Rye KA; Saku K, 2009, 'Reconstituted high-density lipoprotein attenuates postinfarction left ventricular remodeling in rats', Atherosclerosis, 203, pp. 137 - 144, http://dx.doi.org/10.1016/j.atherosclerosis.2008.05.056

Tabet F; Rye KA, 2009, 'High-density lipoproteins, inflammation and oxidative stress', Clinical Science, 116, pp. 87 - 98, http://dx.doi.org/10.1042/CS20080106

Wu B; Yan L; Charlton F; Rye K-A, 2009, 'Abstract: 1008 NIACIN INHIBITS ACUTE VASCULAR INFLAMMATION IN RABBITS', Atherosclerosis Supplements, 10, pp. e383 - e383, http://dx.doi.org/10.1016/s1567-5688(09)70375-7

Fryirs M; Barter P; Tabet F; Heather A; Rye K, 2009, 'Abstract: 1043 HIGH DENSITY LIPOPROTEINS (HDL) INCREASE PANCREATIC B-CELL INSULIN SECRETION', Atherosclerosis Supplements, 10, pp. e403 - e403, http://dx.doi.org/10.1016/s1567-5688(09)70395-2

Heather A; Li X-H; McGrath K; Rye K; Barter P, 2009, 'Abstract: 1066 HIGH DENSITY LIPOPROTEINS (HDLS) INDUCE A MILD OXIDATIVE STRESS RESPONSE IN HUMAN ENDOTHELIAL CELLS THAT INCREASES CELLULAR ANTIOXIDANT PROTEIN EXPRESSION AND PROTECTS AGAINST INFLAMMATORY INSULT', Atherosclerosis Supplements, 10, pp. e415 - e415, http://dx.doi.org/10.1016/s1567-5688(09)70407-6

Bursill C; Castro L; Barter P; Rye K, 2009, 'Abstract: 1095 HIGH DENSITY LIPOPROTEINS (HDL) REDUCE THE EXPRESSION OF CHEMOKINE RECEPTORS CCR2 AND CX3CR1 IN MONOCYTES', Atherosclerosis Supplements, 10, pp. e432 - e432, http://dx.doi.org/10.1016/s1567-5688(09)70423-4

di Bartolo B; Bursill C; Rye K-A; Nicholls S; Heather A; Barter P, 2009, 'Abstract: 1111 ANTI-INFLAMMATORY PROPERTIES OF RECONSITUTED HDL IN A CHRONIC MODEL OF INFLAMMATION', Atherosclerosis Supplements, 10, pp. e441 - e441, http://dx.doi.org/10.1016/s1567-5688(09)70432-5

Li L; Bursill C; Barter P; Rye K, 2009, 'Abstract: 1112 EVIDENCE THAT APOA-II IS ANTI-INFLAMMATORY IN VITRO AND IN VIVO', Atherosclerosis Supplements, 10, pp. e442 - e442, http://dx.doi.org/10.1016/s1567-5688(09)70433-7

Tabet F; Remaley A; Barter P; Rye K-A; Lambert G, 2009, 'Abstract: 1458 THE 5A APOA-I MIMETIC PEPTIDE DISPLAYS ANTI-INFLAMMATORY AND ANTIOXIDANT PROPERTIES MEDIATED BY ABCA1', Atherosclerosis Supplements, 10, pp. e98 - e98, http://dx.doi.org/10.1016/s1567-5688(09)70103-5

Liong E; McGrath K; Tan J; Li X-H; Dy V; Barter P; Rye K; Heather A, 2009, 'Abstract: 1510 ROLE OF 3B-HYDROXYSTEROID-[DELTA]24 REDUCTASE IN MEDIATING THE ANTI-INFLAMMATORY EFFECTS OF HIGH-DENSITY LIPOPROTEINS IN ENDOTHELIAL CELLS', Atherosclerosis Supplements, 10, pp. e464 - e464, http://dx.doi.org/10.1016/s1567-5688(09)70455-6

Zerrad-Saadi A; Therond P; Couturier M; Chantepie S; Rye K; Chapman M; Kontush A, 2009, 'Abstract: 82 MECHANISMS IMPLICATED IN THE POTENT PROTECTION OF LDL FROM OXIDATIVE STRESS MEDIATED BY SMALL, DENSE HDL3', Atherosclerosis Supplements, 10, pp. e221 - e221, http://dx.doi.org/10.1016/s1567-5688(09)70225-9

Bursill C; Castro L; Barter P; Rye K, 2009, 'Abstract: P1151 HIGH DENSITY LIPOPROTEINS (HDL) REDUCE CHEMOKINE EXPRESSION IN MONOCYTES AND ENDOTHELIAL CELLS', Atherosclerosis Supplements, 10, pp. e1177 - e1177, http://dx.doi.org/10.1016/s1567-5688(09)71144-4

di Bartolo B; Bursill C; Rye K-A; Nicholls S; Heather A; Barter P, 2009, 'Abstract: P1154 IN VITRO PROPERTIES OF AN APOLIPOPROTEIN A-I MIMETIC PEPTIDE', Atherosclerosis Supplements, 10, pp. e1180 - e1180, http://dx.doi.org/10.1016/s1567-5688(09)71147-x

Tabet F; Lambert G; Jenkins A; Barter P; Rye K-A, 2009, 'Abstract: P1202 THE ANTI-INFLAMMATORY AND ANTIOXIDANT PROPERTIES OF APOLIPOPROTEIN (APO) A-I FROM DIABETIC PATIENTS ARE IMPAIRED', Atherosclerosis Supplements, 10, pp. e309 - e309, http://dx.doi.org/10.1016/s1567-5688(09)70309-5

Reimers G; Rickards J; Chan P; Rye K-A; Cohn J; Jackson C; Barter P; Rodgers K, 2009, 'Abstract: P290 PREVENTION OF RUPTURE OF ESTABLISHED ATHEROSCLEROTIC PLAQUES BY TREATMENT WITH APOLIPOPROTEIN A-I DUE TO MODULATION OF SMOOTH MUSCLE CELL PHENOTYPE', Atherosclerosis Supplements, 10, pp. e598 - e598, http://dx.doi.org/10.1016/s1567-5688(09)70585-9

Patel S; Puranik R; Nakhla S; Lundman P; Stocker R; Wang X; Lambert G; Rye KA; Barter P; Nicholls S; Celermajer D, 2009, 'Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-intlammatory capacity of high density lipoproteins', Atherosclerosis, 204, pp. 424 - 428, http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T12-4TYYTB7-1&_user=37161&_coverDate=06%2F30%2F2009&_rdoc=1&_fmt=high&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000004218&_version=1&_urlVersion=0&_userid=37161&md5=aacd896d5e64a6ceaccd8e1f5f68fd7d

Heather AK; Li XH; McGrath KCY; Rye KA; Barter PJ, 2009, 'HDL induces anergy to proinflammatory cytokines in endothelial cells through a mild oxidative stress response', Heart, Lung and Circulation, 18, pp. S243 - S243, http://dx.doi.org/10.1016/j.hlc.2009.05.602

Tan JTM; Rye KA; Barter PJ; Heather AK, 2009, 'Role of DHCR24 in Mediating the Anti-inflammatory Effects of HDL in Human Coronary Artery Endothelial Cells', Heart, Lung and Circulation, 18, pp. S2 - S2, http://dx.doi.org/10.1016/j.hlc.2009.05.004

Tabet F; Lambert G; Jenkins AJ; Barter PJ; Rye KA, 2009, 'The anti-oxidant and anti-inflammatory properties of lipid-free and lipid-associated apolipoprotein A-I, in diabetes', Heart, Lung and Circulation, 18, pp. S249 - S249, http://dx.doi.org/10.1016/j.hlc.2009.05.614

Tabet F; Remaley AT; Barter PJ; Rye KA; Lambert G, 2009, 'The Cardioprotective Properties of the Novel 5A Apolipoprotein A-I Mimetic Peptide are Mediated via the ABCA1 Transporter', Heart, Lung and Circulation, 18, pp. S124 - S124, http://dx.doi.org/10.1016/j.hlc.2009.05.283

Rye KA; Barter PJ, 2008, 'Antiinflammatory actions of HDL. A new insight', Arteriosclerosis, Thrombosis, and Vascular Biology, 28, pp. 1890 - 1891, http://dx.doi.org/10.1161/ATVBAHA.108.173575

Silva RAGD; Huang R; Morris J; Fang J; Gracheva EO; Ren G; Kontush A; Jerome WG; Rye KA; Davidson WS, 2008, 'Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes', Proceedings of the National Academy of Sciences of the United States of America, 105, pp. 12176 - 12181, http://dx.doi.org/10.1073/pnas.0803626105

Nobécourt E; Zeng J; Davies MJ; Brown BE; Yadav S; Barter PJ; Rye KA, 2008, 'Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I', Diabetologia, 51, pp. 1008 - 1017, http://dx.doi.org/10.1007/s00125-008-0986-z

Lambert G; Ancellin N; Charlton F; Comas D; Pilot J; Keech A; Patel S; Sullivan DR; Cohn JS; Rye KA; Barter PJ, 2008, 'Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment', Clinical Chemistry, 54, pp. 1038 - 1045, http://dx.doi.org/10.1373/clinchem.2007.099747

Imaizumi S; Miura SI; Nakamura K; Kiya Y; Uehara Y; Zhang B; Matsuo Y; Urata H; Ideishi M; Rye KA; Sata M; Saku K, 2008, 'Antiarrhythmogenic Effect of Reconstituted High-Density Lipoprotein Against Ischemia/Reperfusion in Rats', Journal of the American College of Cardiology, 51, pp. 1604 - 1612, http://dx.doi.org/10.1016/j.jacc.2007.12.040

Uehara Y; Tsuboi Y; Zhang B; Miura SI; Baba Y; Higuchi MA; Yamada T; Rye KA; Saku K, 2008, 'POPC/apoA-I discs as a potent lipoprotein modulator in Tangier disease', Atherosclerosis, 197, pp. 283 - 289, http://dx.doi.org/10.1016/j.atherosclerosis.2007.04.025

Homer VM; Marais AD; Charlton F; Laurie AD; Hurndell N; Scott R; Mangili F; Sullivan DR; Barter PJ; Rye KA; George PM; Lambert G, 2008, 'Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa', Atherosclerosis, 196, pp. 659 - 666, http://dx.doi.org/10.1016/j.atherosclerosis.2007.07.022

Barter PJ; Rye KA, 2008, 'Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?', Arteriosclerosis, Thrombosis, and Vascular Biology, 28, pp. 39 - 46, http://dx.doi.org/10.1161/ATVBAHA.107.148817

Puranik R; Bao S; Nobecourt E; Nicholls SJ; Dusting GJ; Barter PJ; Celermajer DS; Rye KA, 2008, 'Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo', Atherosclerosis, 196, pp. 240 - 247, http://dx.doi.org/10.1016/j.atherosclerosis.2007.05.008

Settasatian N; Barter PJ; Rye KA, 2008, 'Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein', Journal of Lipid Research, 49, pp. 115 - 126, http://dx.doi.org/10.1194/jlr.M700220-JLR200

Kim WS; Elliott DA; Kockx M; Kritharides L; Rye K; Jans D; Garner B, 2008, 'Analysis of apolipoprotein E nuclear localization using green fluorescent protein and biotinylation approaches', Biochemical Journal, 409, pp. 701 - 709, http://dx.doi.org/10.1042/BJ20071261

Chan LL; Kim WS; Kwok JB; Hill AF; Cappai R; Rye K; Garner B, 2008, 'ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro', Journal of Neurochemistry, 106, pp. 793 - 804

Glaros EN; Kim WS; Quinn CM; Jessup W; Rye K; Garner B, 2008, 'Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice', Journal of Lipid Research, 49, pp. 324 - 331, http://dx.doi.org/10.1194/jlr.M700261-JLR200

Miura S; Imaizumi S; Kiya Y; Sata M; Rye KA; Saku K, 2008, 'RECONSTITUTED HDL THERAPY FOR CARDIOVASCULAR DISEASE', Atherosclerosis Supplements, 9, pp. 17 - 17, http://dx.doi.org/10.1016/s1567-5688(08)70061-8

Patel S; Sieveking D; Barter P; Rye K-A; Celermajer D; Ng M, 2008, 'Reconstituted High-density Lipoproteins (rHDL), Lipid-free Apolipoprotein A-I (lipid-free apoA-I) and Plasma HDL Inhibit Tubulogenesis in an Endothelial Cell-specific Model of Angiogenesis', Heart, Lung and Circulation, 17, pp. S16 - S16, http://dx.doi.org/10.1016/j.hlc.2008.05.034

Glaros EN; Kim WS; Rye K; Shayman J; Garner B, 2008, 'Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice', Journal of Lipid Research, 49, pp. 1677 - 1681, http://dx.doi.org/10.1194/jlr.E800005-JLR200

Patel S; Drew B; Nakhla S; Barter P; Rye K-A; Kingwell B; Celermajer D, 2008, 'The Anti-inflammatory Capacity of Human High Density Lipoproteins (HDL) is Significantly Enhanced after Infusion of Reconstituted HDL “In Vivo”', Heart, Lung and Circulation, 17, pp. S2 - S3, http://dx.doi.org/10.1016/j.hlc.2008.05.003

Ng TWK; Watts GF; Barrett PHR; Rye KA; Chan DC, 2007, 'Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: Associations with changes in plasma retinol-binding protein-4 and adiponectin levels', Diabetes Care, 30, pp. 2945 - 2950, http://dx.doi.org/10.2337/dc07-0768

Back to profile page